Drug
HS-10374 clinical trials
Keep track of what changes. Save the HS-10374 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
6 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 0
Hansoh BioMedical R&D Company (5) · Jiangsu Hansoh Pharmaceutical Co., Ltd. (1)
Studies
Open first, then newest update. How each study uses HS-10374 is read from its arms, and is right about nine times in ten.
Testing it · 6
- A Study to Evaluate Efficacy and Safety of HS-10374 for Mild-to-moderate Plaque PsoriasisNot yet recruitingPhase 2Hansoh BioMedical R&D CompanyNCT06926582Written as HS-10374 6mg tablets
- A Study to Confirm Efficacy and Safety of HS-10374 for Moderate to Severe Plaque PsoriasisNot yet recruitingPhase 3Hansoh BioMedical R&D CompanyNCT06672393Written as HS-10374 6mg tablets
- Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic ArthritisRecruitingPhase 2Hansoh BioMedical R&D CompanyNCT06176508Written as HS-10374
- A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque PsoriasisRecruitingPhase 2Hansoh BioMedical R&D CompanyNCT06077331Written as HS-10374 tablets 1mg
- A Drug-Drug Interaction Study Between HS-10374 Tablets and Drospirenone and Ethinyl Estradiol Tablets(Yasmin®)CompletedPhase 1Hansoh BioMedical R&D CompanyNCT07181343Written as HS-10374 tablets
- A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10374 in Healthy SubjectsCompletedPhase 1Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT06033742Written as HS-10374 tablets